BACKGROUND: Human T cell lymphotropic virus type I (HTLV-I) is associated with specific manifestations such as adult T cell lymphoma/leukemia (ATLL), HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP), HTLV-I-associated uveitis, and infective dermatitis associated with HTLV-I (IDH). Although ATLL and IDH are considered specific manifestations of HTLV-I infection, several dermatological manifestations have been described in HTLV-I seropositive patients. OBJECTIVES: This study was conducted to determine the prevalences of skin lesions in patients infected with HTLV-I in an area of Brazil endemic for HTLV-I infection and to compare these prevalences with those in seronegative individuals in the same region. METHODS: A prevalence study was conducted between 2008 and 2010 with two groups of individuals comprising, respectively, 179 HTLV-I seropositive (positive enzyme-linked immunosorbent assay [ELISA] and positive Western blot analysis) and 193 HTLV-I seronegative individuals (ELISA-negative). The subjects were selected on a random basis and evaluated using a questionnaire to obtain epidemiological and clinical data. A physical examination was performed to verify the presence of skin lesions. RESULTS: Superficial mycoses were found in 54 (30.2%) seropositive subjects and in 26 (13.5%) of the seronegative group (P < 0.001). Xerosis was found in 39.1% of HTLV-I infected subjects and in 9.3% of seronegative controls (P < 0.001). Ichthyosis was diagnosed in nine (5.0%) HTLV-I seropositive subjects but in none of the control group (P = 0.001). A diagnosis of seborrheic dermatitis was made in 43 (24.0%) HTLV-I infected subjects and in 24 (12.4%) seronegative controls (P = 0.004). Furthermore, dermatological manifestations were more intense in the HTLV-I seropositive group. CONCLUSIONS: Several dermatological manifestations are more common and more severe in HTLV-I seropositive subjects. The presence of these manifestations in an area endemic for HTLV-I infection may provide some clues in the investigation of this infection.
BACKGROUND:Human T cell lymphotropic virus type I (HTLV-I) is associated with specific manifestations such as adult T cell lymphoma/leukemia (ATLL), HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP), HTLV-I-associated uveitis, and infective dermatitis associated with HTLV-I (IDH). Although ATLL and IDH are considered specific manifestations of HTLV-I infection, several dermatological manifestations have been described in HTLV-I seropositive patients. OBJECTIVES: This study was conducted to determine the prevalences of skin lesions in patients infected with HTLV-I in an area of Brazil endemic for HTLV-I infection and to compare these prevalences with those in seronegative individuals in the same region. METHODS: A prevalence study was conducted between 2008 and 2010 with two groups of individuals comprising, respectively, 179 HTLV-I seropositive (positive enzyme-linked immunosorbent assay [ELISA] and positive Western blot analysis) and 193 HTLV-I seronegative individuals (ELISA-negative). The subjects were selected on a random basis and evaluated using a questionnaire to obtain epidemiological and clinical data. A physical examination was performed to verify the presence of skin lesions. RESULTS: Superficial mycoses were found in 54 (30.2%) seropositive subjects and in 26 (13.5%) of the seronegative group (P < 0.001). Xerosis was found in 39.1% of HTLV-I infected subjects and in 9.3% of seronegative controls (P < 0.001). Ichthyosis was diagnosed in nine (5.0%) HTLV-I seropositive subjects but in none of the control group (P = 0.001). A diagnosis of seborrheic dermatitis was made in 43 (24.0%) HTLV-I infected subjects and in 24 (12.4%) seronegative controls (P = 0.004). Furthermore, dermatological manifestations were more intense in the HTLV-I seropositive group. CONCLUSIONS: Several dermatological manifestations are more common and more severe in HTLV-I seropositive subjects. The presence of these manifestations in an area endemic for HTLV-I infection may provide some clues in the investigation of this infection.
Authors: Maria E R Lenzi; Tullia Cuzzi-Maya; André L A Oliveira; Maria J Andrada-Serpa; Abelardo Q-C Araújo Journal: Clin Infect Dis Date: 2003-01-30 Impact factor: 9.079
Authors: M Mochizuki; T Watanabe; K Yamaguchi; K Yoshimura; S Nakashima; M Shirao; S Araki; K Takatsuki; S Mori; N Miyata Journal: Am J Ophthalmol Date: 1992-08-15 Impact factor: 5.258
Authors: Elizabeth M Maloney; Stefan Z Wiktor; Paulette Palmer; Beverley Cranston; Ernest J Pate; Sylvia Cohn; Norma Kim; Wendell Miley; Terry L Thomas; William A Blattner; Barrie Hanchard Journal: Pediatrics Date: 2003-08 Impact factor: 7.124
Authors: Camila F Amorim; Anselmo S Souza; Angela G Diniz; Natália B Carvalho; Silvane B Santos; Edgar M Carvalho Journal: PLoS Negl Trop Dis Date: 2014-12-18
Authors: Elías Quintero-Muñoz; Daniel Martin Arsanios; María Fernanda Estupiñán Beltrán; Juan David Vera; Catalina Palacio Giraldo; Omar Velandia; Carlos Mauricio Calderon Journal: BMC Infect Dis Date: 2021-07-06 Impact factor: 3.090
Authors: Luiz C F Romanelli; Débora M Miranda; Anna B F Carneiro-Proietti; Marcelo Mamede; Herika M M Vasconcelos; Marina L Martins; Anísia S D Ferreira; Daniela V F Rosa; Jonas J Paula; Marco A Romano-Silva; Rodrigo Nicolato Journal: PLoS Negl Trop Dis Date: 2018-08-27